Prior approval / evidence record
NMPA-Uzbekistan Pharmaceutical Safety Center MoU (2025): no recognition effect
- Statement
On 27 June 2025 NMPA Commissioner Li Li and Alisher Temirov, Director of the Pharmaceutical Safety Center of the Uzbekistan Ministry of Health, signed in Beijing the 'Memorandum of Understanding between the NMPA of the PRC and the Pharmaceutical Safety Center of the Ministry of Health of the Republic of Uzbekistan on regulatory cooperation for drugs and medical devices'. The MoU establishes cooperation and exchange; it does not add NMPA to Uzbekistan's recognition list.
- Source Jurisdiction Id
china
- Source Authority Id
nmpa
- Source Approval
China NMPA medical device registration certificate (Class II/III) or Class I filing record
- Target Jurisdiction Id
uzbekistan
- China Classes In Scope
Not class-specific; regulatory-cooperation MoU (drugs and medical devices)
- Edge Type
Cooperation Mou
- Market Access Strength
none
- Regulatory Layer
Product Marketing
- Local Application Required
Yes
- Target Decision Retained
Yes
- Cooperation/exchange instrument; no mutual recognition of registrations
- Resolution 738 adopted five months later (24.11.2025) still omits NMPA from the recognition list
- Independent verification is incomplete. Treat this record as a research lead, not a confirmed benefit or exclusion; see the 2026-09-15 independent review.
Effective from 2025-06-27
Source passage: 6月27日，国家药监局局长李利在京会见乌兹别克斯坦卫生部药品安全中心主任阿利舍尔•特米罗夫一行，双方就进一步加强中乌在药品监管领域的交流合作进行了深入务实交流，并签署《中华人民共和国国家药品监督管理局与乌兹别克斯坦共和国卫生部药品安全中心关于药品和医疗器械监管合作谅解备忘录》。
